Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.
The merger deal between Abbott Laboratories (ABT) and Alere (ALR) has become an extended battle, and Wall Street analysts have been closely watching the ongoing developments in this deal.
On December 7, 2016, Scott Stoffel, divisional vice president of external communications at Abbott Laboratories, noted, “Alere is no longer the company Abbott agreed to buy 10 months ago.”
Abbott Laboratories (ABT) is focused on the strategic restructuring of its business while dealing with the acquisition difficulties with Alere.
Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.
On November 22, 2016, Boston Scientific (BSX) announced the completion of its acquisition of EndoChoice Holdings. The deal was valued at $210 million in cash at a price of $8.00 per share.
On November 29, 2016, Nevro Corp. (NVRO) filed a lawsuit against Boston Scientific, claiming patent infringement on its patents for Senza and HF10 spinal cord stimulation therapies for chronic back pain.
Developed by Boston Scientific (BSX), HeartLogic is a system of sensors that can be attached to defibrillator devices. These sensors can monitor the patient and predict heart failure events.
Boston Scientific (BSX) stock has fallen ~7.4% since the release of the company’s 3Q16 earnings on October 26, 2016.
In a November 30 survey of 26 brokerage companies, ~81% of these analysts rated Boston Scientific (BSX) as a “buy” and 19% rated it as a “hold.” None of the analysts rated Boston Scientific as a “sell.”
According to Kinder Morgan (KMI), the Trans Mountain Pipeline Expansion project will generate a number of benefits for Canada and the US.
According to the Alberta Oil Sands Industry quarterly update for the period ending October 2016, Canada has the third-largest oil reserves in the world after Saudi Arabia and Venezuela.
Kinder Morgan’s (KMI) TMP (Trans Mountain Pipeline) expansion got approval from the Canadian government on November 29.
With Trump’s plan to scrap the Clean Power Plan and strong support in favor of the plan from many sectors in the country, there will likely be resistance.
On November 22, 2016, President-elect Donald Trump released his agenda for the next 100 days. He still intends to scrap the Clean Power Plan.
Mylan believes that it may be the first generic pharmaceutical company to file a complete ANDA with paragraph IV certification for Teva’s Copaxone 40.
Copaxone 40 mg litigations On August 24, 2016, Mylan (MYL) announced that the PTO (US Patent and Trademark Office) invalidated patents 8,232,250 and 8,399,413, which are related to Teva Pharmaceutical…
For RBNZ (Reserve Bank of New Zealand) Governor Graeme Wheeler, coming out with a cut was a no-brainer to markets. Markets expected a rate cut.
Qualcomm has filed a lawsuit against Meizu, which is backed by Alibaba (BABA), for using its technology without paying licensing fees.
General Electric (GE) has a Wall Street analyst consensus rating of “buy.” Of the 20 analysts surveyed by Bloomberg, 11 gave the company “buy” ratings.